Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04912024 · ClinicalTrials.gov registry record
Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
A clinical trial, sponsored by Outset Medical.
- Completed
- Registry status
- 458
- Enrollment target
NCT04912024: Completed study, sponsored by Outset Medical.
NCT04912024 is a clinical trial that has completed, run by Outset Medical. The registered enrollment target is 458 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04912024 has completed, sponsored by Outset Medical.
- COMPLETED
- Registry status
- 458 participants
- Enrollment target
Study Summary
Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
Primary Outcome
Change in Blood Urea Nitrogen
Interventions
- DEVICE Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System
- DEVICE Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2022-06-15 |
What the finished NCT04912024 record still lists
NCT04912024 is an observational study that tracks outcomes without assigning an intervention. The registered 458 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System is the first listed.
NCT04912024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04912024 about?
NCT04912024 is a clinical study titled "Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study". Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
What is the current status of trial NCT04912024?
This trial is currently completed. The enrollment target is 458 participants. The study started on 2021-05-15. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT04912024?
The interventions under investigation include: Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System (DEVICE), Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems (DEVICE).
Who is sponsoring clinical trial NCT04912024?
This trial is sponsored by Outset Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05856942 · 458 participants · NA
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
- NCT06201676 · 458 participants · Phase 4
Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI